| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED NOVEMBER 2021. Refer to TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation for reference only. |
||
|
||
Medicine details |
||
| Medicine name | mexiletine (Namuscla®) | |
| Formulation | 167 mg hard capsules | |
| Reference number | 2309 | |
| Indication | Symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders |
|
| Company | Lupin (Europe) Limited | |
| BNF chapter | Musculoskeletal & joint diseases | |
| Assessment type | Non-submission | |
| Status | Superseded | |
| Date of issue | 02/04/2019 | |
| NICE guidance | TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders |
|